Recent News

AXIM Biotechnologies CEO Issues Letter to Shareholders

Summary: In 2022, AXIM® finalized optimization of its R&D and manufacturing infrastructure to be used in its diagnostic program AXIM will continue to generate revenue from its two FDA-cleared dry eye disease (DED) diagnostic tests through commercialization partner...

Latest Annual Filing

Fiscal Year Ended Dec 31, 2021